How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,785 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Expression of FK506-binding protein 51 (FKBP51) in Mycosis Fungoides. (Abstract)

Expression of FK506-binding protein 51 (FKBP51) in Mycosis Fungoides. Mycosis fungoides (MF) is the major subtype of cutaneous T-cell lymphomas (CTCL). It usually has a prolonged indolent clinical course with a minority of cases acquiring a more aggressive biological profile and resistance to conventional therapies, partially attributed to the persistent activation of nuclear factor-kappa B (NF-κB) pathway. In the last decade, several papers suggested an important role for the FK506-binding

2017 Journal of the European Academy of Dermatology and Venereology

122. Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. (Abstract)

Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. Mycosis fungoides (MF) and parapsoriasis are characterized by malignant proliferation and chronic inflammation, which may affect the risk for venous thromboembolism (VTE).To examine the risk for VTE in patients with MF and parapsoriasis.We conducted a nationwide population-based cohort study in Denmark to examine the relative risk (RR) of VTE in 525 patients

2017 Journal of American Academy of Dermatology

123. Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and sezary syndrome. Full Text available with Trip Pro

Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and sezary syndrome. While mycosis fungoides (MF) is typically an indolent malignancy, it may infrequently undertake an aggressive course. We used proteomic analyses to identify a biomarker of the aggressive course of MF. Results of this investigation demonstrated that PARP-1, heat-shock protein family A (Hsp70) member 1 like (HSAP1L), Hsp70 member 1A (HSPA1A), ATP-depending RNA helicase (DDX17) and the α-isoform

2017 Experimental Dermatology

124. Early stage mycosis fungoides screening investigations: a retrospective analysis of 440 cases. (Abstract)

Early stage mycosis fungoides screening investigations: a retrospective analysis of 440 cases. 29220538 2018 06 07 1468-3083 32 6 2018 Jun Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Early-stage mycosis fungoides screening investigations: a retrospective analysis of 440 cases. e217-e218 10.1111/jdv.14735 Bawazir M A MA Division of Dermatology, Department of Medicine, University of Toronto, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada

2017 Journal of the European Academy of Dermatology and Venereology

125. Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Full Text available with Trip Pro

Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Mycosis fungoides (MF) is the most frequent form of cutaneous T-cell lymphoma. The disease often takes an indolent course, but in approximately one-third of the patients, the disease progresses to an aggressive malignancy with a poor prognosis. At the time of diagnosis, it is impossible to predict which patients develop severe disease and are in need of aggressive treatment

2017 Blood

126. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Full Text available with Trip Pro

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Advanced-stage mycosis fungoides (MF)/Sézary syndrome (SS) patients are weighted by an unfavorable prognosis and share an unmet clinical need of effective treatments. International guidelines are available detailing treatment options for the different stages but without recommending treatments in any particular order due

2017 Annals of Oncology

127. Trichoscopic spectrum of folliculotropic mycosis fungoides. (Abstract)

Trichoscopic spectrum of folliculotropic mycosis fungoides. 28924975 2018 03 14 1468-3083 32 3 2018 Mar Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Trichoscopic spectrum of folliculotropic mycosis fungoides. e107-e108 10.1111/jdv.14596 Sławińska M M Department of Dermatology, Venerology and Allergology, Medical University of Gdańsk, Gdańsk, Poland. Sobjanek M M Department of Dermatology, Venerology and Allergology, Medical University

2017 Journal of the European Academy of Dermatology and Venereology

128. No Viral Transcripts Associated with Folliculotropic Mycosis Fungoides Using a High Throughput Sequencing Approach. Full Text available with Trip Pro

No Viral Transcripts Associated with Folliculotropic Mycosis Fungoides Using a High Throughput Sequencing Approach. is missing (Short communication).

2017 Acta Dermato-Venereologica

129. The Effect of Phototherapy on Progression to Tumors in Patients with Patch and Plaque Stage of Mycosis Fungoides. Full Text available with Trip Pro

The Effect of Phototherapy on Progression to Tumors in Patients with Patch and Plaque Stage of Mycosis Fungoides. Phototherapy has been a mainstay in the treatment of mycosis fungoides (MF). However, the recent findings of UV-induced p53 mutations in advanced MF suggest that phototherapy may contribute to disease progression.The objective of this study was to evaluate the effect of phototherapy on the time to tumor progression and overall survival in MF.Retrospective analysis of patients seen

2017 Journal of Dermatological Treatment

130. The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. (Abstract)

The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. Total skin electron beam radiation therapy (TSEB) is a very effective treatment of mycosis fungoides. Following reports of similar durations of response to lower doses of TSEB, a low-dose schedule of TSEB was introduced in the United Kingdom.A protocol of 12 Gy in 8 fractions over a period of 2 weeks was agreed on by use of the Stanford University (...) with stage IB disease compared with 11.3 months in patients with stage IIB (P=.003; hazard ratio, 2.66) and 10.2 months in patients with stage III (P=.002; hazard ratio, 4.62). The treatment was well tolerated with lower toxicity than higher-dose schedules.The low-dose TSEB schedule of 12 Gy in 8 fractions over a period of 2 weeks is well tolerated and is an effective option for patients with mycosis fungoides.Copyright © 2017 Elsevier Inc. All rights reserved.

2017 Biology and Physics

131. Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study. Full Text available with Trip Pro

Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study. Immunodeficiency (ID) correlates with worse outcomes and decreased immune checkpoint molecule expression in melanoma. The impact of ID in mycosis fungoides (MF) is unknown.Our goal was to evaluate the impact of ID in MF.We conducted a case-control study of 17 patients with MF and ID versus age-, stage-, and race-matched

2017 Journal of American Academy of Dermatology

132. Combination of low-dose total skin electron beam therapy and subsequent localized skin electron beam therapy as a therapeutic option for advanced-stage mycosis fungoides. (Abstract)

Combination of low-dose total skin electron beam therapy and subsequent localized skin electron beam therapy as a therapeutic option for advanced-stage mycosis fungoides. Electron beam therapy (EBT) is an established treatment for mycosis fungoides (MF), but evidence for the use of EBT in advanced cutaneous conditions is limited, and optimal scheduling of the regimen for such conditions remains unclear. We report the case of a 44-year-old woman diagnosed with MF with widespread cutaneous

2017 Clinical & Experimental Dermatology

133. Mycosis fungoides occurring at the site of previous herpes zoster eruption. (Abstract)

Mycosis fungoides occurring at the site of previous herpes zoster eruption. Numerous clinicopathological variants of mycosis fungoides have been described in the literature. Dermatomal or zosteriform mycosis fungoides is one reported variant but a clear aetiology has never been documented. We report a case of mycosis fungoides proved by biopsy and immunohistochemistry that developed in a 55-year-old man at the site of previous herpes zoster eruption. We also present a review of the relevant (...) literature to add to the understanding of rare variants of mycosis fungoides and aid in the clinical recognition of zosteriform mycosis fungoides.© 2017 The Australasian College of Dermatologists.

2017 Australasian Journal of Dermatology

134. Standardization of regimens in Narrow-band UVB and PUVA in early stage Mycosis Fungoides: position paper from the Italian Task Force for Cutaneous Lymphomas. (Abstract)

Standardization of regimens in Narrow-band UVB and PUVA in early stage Mycosis Fungoides: position paper from the Italian Task Force for Cutaneous Lymphomas. UV-based (PUVA and narrowband UVB) phototherapy is broadly and commonly used in the treatment of Cutaneous T-cell Lymphomas (CTCL), yet unfortunately, the evidence for the efficacy of these treatments is based only on case series or prospective but non-randomized studies. Therefore, no internationally approved guidelines exist

2017 Journal of the European Academy of Dermatology and Venereology

135. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Full Text available with Trip Pro

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. In order to provide a common standard for the treatment of mycosis fungoides (MF) and Sézary syndrome (SS), the European Organisation for Research and Treatment of Cancer-Cutaneous Lymphoma Task Force (EORTC-CLTF) published in 2006 its consensus recommendations for the stage-adapted selection of management options for these neoplasms. Since

2017 European Journal of Cancer

136. Computed Tomography scanning in mycosis fungoides - optimising the balance between benefit and harm. (Abstract)

Computed Tomography scanning in mycosis fungoides - optimising the balance between benefit and harm. 28498608 2018 12 20 1365-2133 178 2 2018 02 The British journal of dermatology Br. J. Dermatol. Computed tomography scanning in mycosis fungoides: optimizing the balance between benefit and harm. 563-564 10.1111/bjd.15657 Spencer A A 0000-0003-3386-8458 Department of Dermatology, University Hospitals Birmingham, Mindelsohn Way, Edgbaston, Birmingham B15 2GW, U.K. Gazzani P P Department

2017 British Journal of Dermatology

137. Secondary Cutaneous Amyloidosis in a Patient with Mycosis Fungoides Full Text available with Trip Pro

Secondary Cutaneous Amyloidosis in a Patient with Mycosis Fungoides Secondary cutaneous amyloidosis refers to clinically unapparent amyloid deposits within the skin in association with a pre-existing skin condition or skin tumors, such as basal cell carcinoma, porokeratosis, solar elastosis, Bowen's disease, and mycosis fungoides. A 70-year-old woman presented with a 6-month history of asymptomatic multiple yellowish plaques on both legs. She had been diagnosed with mycosis fungoides 7 years (...) ago and was treated with psoralen and ultraviolet A radiation (PUVA) therapy, narrow-band ultraviolet B (UVB) therapy, and acitretin for 5 years. Finally, she reached complete remission of mycosis fungoides. However, new yellowish lesions started to appear 1 year after discontinuing the phototherapy. A physical examination revealed multiple yellowish plaques on both extremities. The plaques were well circumscribed and slightly elevated. All laboratory tests were normal. A biopsy specimen showed

2017 Annals of dermatology

138. Sudden aggravated CD8+ mycosis fungoides accompanied by hidden adenocarcinoma of the colon Full Text available with Trip Pro

Sudden aggravated CD8+ mycosis fungoides accompanied by hidden adenocarcinoma of the colon 28243625 2019 02 26 2352-5126 3 2 2017 Mar JAAD case reports JAAD Case Rep Sudden aggravated CD8 + mycosis fungoides accompanied by hidden adenocarcinoma of the colon. 83-86 10.1016/j.jdcr.2016.12.003 Ahn Hye-Jin HJ Department of Dermatology, School of Medicine, Kyung Hee University, Seoul, Korea. Shin Eun Jae EJ Department of Dermatology, School of Medicine, Kyung Hee University, Seoul, Korea. Gwak Min (...) -Jae MJ Department of Dermatology, School of Medicine, Kyung Hee University, Seoul, Korea. Jeong Ki-Heon KH Department of Dermatology, School of Medicine, Kyung Hee University, Seoul, Korea. Shin Min Kyung MK Department of Dermatology, School of Medicine, Kyung Hee University, Seoul, Korea. eng Case Reports 2017 02 21 United States JAAD Case Rep 101665210 2352-5126 CD8+ mycosis fungoides CTCL, cutaneous T-cell lymphoma FOLFOX, folinic acid, fluorouracil, oxaliplatin MF, mycosis fungoides colon

2017 JAAD Case Reports

139. Fulminant Mycosis Fungoides with Tissue Eosinophilia: A Unique Presentation of Two Cases with Acro-Periorbital Ulceration and An Aggressive Clinical Course Full Text available with Trip Pro

Fulminant Mycosis Fungoides with Tissue Eosinophilia: A Unique Presentation of Two Cases with Acro-Periorbital Ulceration and An Aggressive Clinical Course We describe two unique cases of fulminant mycosis fungoides with remarkably similar and aggressive clinical courses resulting in death. Both cases demonstrated ulcerated palmar and periorbital plaques and marked tissue eosinophilia, which was confirmed by T-cell receptor γ chain gene rearrangement studies to display identical monoclonality (...) at temporally and anatomically distinct sites. Dense eosinophilic infiltrates on biopsy led to misdiagnosis of inflammatory dermatoses in both instances. While mycosis fungoides may be challenging to diagnose histologically, the presence of eosinophils in progressive disease may herald a poor prognosis and should not exclude the diagnosis.

2017 Journal of molecular biomarkers & diagnosis

140. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome Full Text available with Trip Pro

Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome Chemotherapy-induced peripheral neuropathy (CIPN) is common, frequently limits chemotherapy dosing, and negatively impacts quality of life. The National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0, and the Total Neuropathy Score clinical version (TNSc) are both validated scores to quantify peripheral neuropathy (PN (...) ), with the TNSc being more sensitive to clinical changes. Mycosis fungoides and Sézary syndrome (MF/SS) are characterized by a chronic course, where current therapies are generally non-curative and treatment toxicities have the potential for significant lasting effects. Brentuximab vedotin (BV) is an antibody-drug-conjugate composed of an anti-CD30 monoclonal antibody linked to the microtubule-disrupting agent, monomethyl auristatin E, with a known associated CIPN. In our phase II clinical trial of BV in MF

2017 Journal of neuro-oncology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>